Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2695 SEK | +1.51% |
|
+0.37% | -33.87% |
01/07 | Vivesto AB Receives Positive Cantrixil Preclinical Efficacy Data | CI |
23/05 | Vivesto AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-33.87% | 1.35Cr | |
+55.35% | 82TCr | |
+31.99% | 60TCr | |
-0.10% | 38TCr | |
+15.47% | 32TCr | |
+13.10% | 31TCr | |
+12.84% | 25TCr | |
+16.32% | 25TCr | |
+16.54% | 18TCr | |
+4.31% | 17TCr |
- Stock Market
- Equities
- VIVE Stock
- News Vivesto AB
- Transcript : Oasmia Pharmaceutical AB - Special Call